Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

418
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
418
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.9K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.9K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Hematopoiesis01:21

Hematopoiesis

8.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue expression of miR-504-5p and miR-429 as diagnostic biomarkers for endometrial cancer and endometrial intraepithelial neoplasia: a pilot study.

The journal of liquid biopsy·2026
Same author

The endogenous oxytocin after manipulative osteopathic treatment in full-term pregnant women.

European review for medical and pharmacological sciences·2024
Same author

First and second branchial arch involvement in mandibulofacial dysostosis Guion-Almeida type.

European journal of paediatric dentistry·2023
Same author

Impact of NNLO QED corrections on lepton-proton scattering at MUSE.

The European physical journal. A, Hadrons and nuclei·2023
Same author

Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Journal of endocrinological investigation·2023
Same author

2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022

Related Experiment Video

Updated: May 5, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.2K

OPSI threat in hematological patients.

B Serio1, L Pezzullo, V Giudice

  • 1Hematology and Hematopoietic Stem Cell Transplant Center, Department of Medicine and Surgery, University of Salerno, Salerno, Italy;

Translational Medicine @ Unisa
|November 20, 2013
PubMed
Summary
This summary is machine-generated.

Overwhelming post-splenectomy infection (OPSI) is a serious risk for patients, especially those with hematological disorders. Immunization and penicillin prophylaxis significantly reduce OPSI development, highlighting the importance of preventive measures.

Keywords:
Overwhelming postsplenectomy infection (OPSI) syndromehematological disorderssplenectomy

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.4K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.0K

Related Experiment Videos

Last Updated: May 5, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.2K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.4K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.0K

Area of Science:

  • Hematology
  • Infectious Diseases
  • Immunology

Background:

  • Overwhelming post-splenectomy infection (OPSI) is a rare but life-threatening sepsis caused by encapsulated bacteria.
  • Patients with hematological disorders and those who have undergone splenectomy face a higher risk of OPSI.

Purpose of the Study:

  • To assess the incidence and risk factors of OPSI in a high-risk cohort of adult splenectomized patients with hematological diseases.
  • To evaluate the effectiveness of immunization and antibiotic prophylaxis in preventing OPSI.

Main Methods:

  • Retrospective analysis of 162 adult splenectomized patients with hematological diseases over 25 years.
  • Comparison between patients who received immunization and those on penicillin prophylaxis.

Main Results:

  • OPSI occurred in 7 patients (4%), all in the non-immunized group except for one fatal case.
  • Immunization against encapsulated bacteria and lifelong penicillin prophylaxis were associated with a significant decrease in OPSI development.
  • OPSI represents a lifelong risk, with cases occurring up to 12 years post-splenectomy.

Conclusions:

  • Current immune prophylaxis strategies significantly reduce OPSI incidence in splenectomized patients.
  • Enhanced patient education and physician awareness are crucial for managing this potentially lethal emergency.
  • OPSI is a lifelong risk, underscoring the need for continuous preventive measures.